Yervoy® (ipilimumab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 **(TTY:** 711**)**
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Please indicate: ☐ Start of treatment: Start date ____/____/____
☐ Continuation of therapy: Date of last treatment ____/____/____

Precertification Requested By: _____ Phone: _____ Fax: _____

A. PATIENT INFORMATION

First Name:	Last Name:		
Address:	City:	State:	ZIP:
Home Phone:	Work Phone:	Cell Phone:	
DOB:	Allergies:	E-mail:	

Current Weight: _____ lbs or _____ kgs Height: _____ inches or _____ cms

B. INSURANCE INFORMATION

Aetna Member ID #: _____
Group #: _____
Insured: _____

Does patient have other coverage? ☐ Yes ☐ No
If yes, provide ID#: _____ Carrier Name: _____
Insured: _____

Medicare: ☐ Yes ☐ No If yes, provide ID #: _____ **Medicaid**: ☐ Yes ☐ No If yes, provide ID #: _____

C. PRESCRIBER INFORMATION

First Name:		Last Name: *(Check One):* ☐ M.D. ☐ D.O. ☐ N.P. ☐ P.A.			
Address:		City:		State:	ZIP:
Phone:	Fax:	St Lic #:	NPI #:	DEA #:	UPIN:
Provider E-mail:		Office Contact Name:		Phone:	

Specialty *(Check one):* ☐ **Oncologist** ☐ **Other**: _____

D. DISPENSING PROVIDER/ADMINISTRATION INFORMATION

Place of Administration:
☐ Self-administered ☐ Physician's Office
☐ Outpatient Infusion Center Phone: _____
Center Name: _____
☐ Home Infusion Center Phone: _____
Agency Name: _____
☐ Administration code(s) (CPT): _____
Address: _____

Dispensing Provider/Pharmacy: *Patient Selected choice*
☐ Physician's Office ☐ Retail Pharmacy
☐ Specialty Pharmacy ☐ Other: _____
Name: _____
Address: _____
Phone: _____ Fax: _____
TIN: _____ PIN: _____

E. PRODUCT INFORMATION

Request is for Yervoy (ipilimumab) Dose: _____ **Frequency:** _____

F. DIAGNOSIS INFORMATION – Please indicate primary ICD Code and specify any other where applicable.

Primary ICD Code: _____ Secondary ICD Code: _____ Other ICD Code: _____

G. CLINICAL INFORMATION – Required clinical information must be completed in its entirety for all precertification requests.

For All Requests (clinical documentation required):

Please list ***all*** additional medications that will be used as part of this treatment regimen (This includes supportive care agents such as anti-emetics, growth factors, etc. A copy of the complete order may be submitted in lieu of listing out each treatment):

Medication: _____ Dose: _____ Frequency: _____
Medication: _____ Dose: _____ Frequency: _____
Medication: _____ Dose: _____ Frequency: _____
Medication: _____ Dose: _____ Frequency: _____
Medication: _____ Dose: _____ Frequency: _____
Medication: _____ Dose: _____ Frequency: _____

☐ Yes ☐ No Will the requested drug be used in combination with Zelboraf (vemurafenib), Tafinlar (dabrafenib) or Mekinist (trametinib)?
→ Please identify which medication will be used: ☐ Zelboraf (vemurafenib) ☐ Tafinlar (dabrafenib) ☐ Mekinist (trametinib)

☐ **Ampullary adenocarcinoma**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
☐ Yes ☐ No Is the tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)?
Please select the clinical setting in which the requested drug will be used:
☐ Progressive disease ☐ Unresectable disease ☐ Metastatic disease ☐ Other

☐ **Bone cancer**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?

Continued on next page

Yervoy® (ipilimumab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 **(TTY:** 711**)**
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

Please indicate the clinical setting in which the requested drug will be used: ☐ Metastatic disease ☐ Unresectable disease ☐ Other
☐ Yes ☐ No ☐ Unknown Is the tumor mutation burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] tumors?
☐ Yes ☐ No Has the disease progressed following prior treatment?
☐ Yes ☐ No Are there satisfactory alternative treatment options available for the patient's disease?

☐ **Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line treatment ☐ Subsequent treatment
Please indicate the clinical setting in which the requested drug will be used: ☐ Unresectable gross residual (R2) disease ☐ Metastatic disease
☐ Resected gross residual (R2) disease ☐ Other
☐ Yes ☐ No ☐ Unknown Is the tumor mutation burden-high (TMB-H)?

☐ **Central nervous system (CNS) with brain metastases in patients with melanoma**
Please indicate the patient's treatment regimen: ☐ Single agent ☐ In combination with nivolumab (Opdivo) ☐ Other

☐ **Colorectal cancer (including appendiceal adenocarcinoma and anal adenocarcinoma)**
☐ Yes ☐ No ☐ Unknown Is the tumor microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)?
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please indicate how many doses of the requested drug will be given: _____

☐ **Cutaneous melanoma**
Please select the clinical setting in which the requested drug will be used:
☐ Adjuvant treatment
→ ☐ Yes ☐ No Is there no evidence of disease following metastasis-directed therapy (i.e., complete resection)?
Please indicate the treatment regimen: ☐ Single agent ☐ In combination with nivolumab (Opdivo) ☐ Other
☐ Limited resectable local recurrence
☐ Yes ☐ No Has the patient received prior treatment with anti-PD-1 therapy?
☐ Yes ☐ No Will the requested drug be used as a single agent?
☐ Treatment of unresectable or metastatic disease
→ Please indicate the disease state: ☐ Metastatic disease ☐ Unresectable disease
☐ Yes ☐ No Has the patient had a disease progression on single-agent anti-programmed death 1 (PD-1) immunotherapy or BRAF-targeted therapy?
→ Please indicate the treatment regimen: ☐ Single agent
☐ In combination with nivolumab (Opdivo) Please indicate how many doses of the requested drug will be given: _____ ☐ Other
→ Please indicate the treatment regimen: ☐ Low dose in combination with pembrolizumab (Keytruda) ☐ Other
Please indicate the place in therapy in which the requested drug will be used: ☐ Initial treatment ☐ Subsequent treatment
☐ Other clinical setting

☐ **Esophageal and Esophagogastric Junction cancers**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
☐ Yes ☐ No ☐ Unknown Is the tumor microsatellite-instability high (MSI-H) or mismatch repair deficient (dMMR)
→ Please select the clinical setting in which the requested drug will be used: ☐ Unresectable locally advanced disease
☐ Recurrent disease ☐ Metastatic disease ☐ Patient is not a surgical candidate ☐ Other
→ Please select the clinical setting in which the requested drug will be used:
☐ Neoadjuvant treatment ☐ Perioperative treatment ☐ Other
☐ Yes ☐ No Will the requested drug be used to treat esophageal or esophagogastric junction adenocarcinoma?
☐ Yes ☐ No Is the patient medically fit for surgery?

☐ **Gastric cancer**
☐ Yes ☐ No Will the requested drug be used to treat gastric adenocarcinoma?
☐ Yes ☐ No ☐ Unknown Is the tumor microsatellite-instability high (MSI-H) or mismatch repair deficient (dMMR)?
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please select the clinical setting in which the requested drug will be used:
☐ Unresectable disease ☐ Recurrent disease ☐ Metastatic disease ☐ Patient is not a surgical candidate ☐ Other
☐ Neoadjuvant treatment OR ☐ Perioperative treatment
→ ☐ Yes ☐ No Is the patient medically fit for surgery?

☐ **Hepatocellular carcinoma**
Please indicate the treatment regimen:
☐ In combination with nivolumab (Opdivo) (4 doses of ipilimumab, followed by Opdivo as a single agent) ☐ Other

Continued on next page

Yervoy® (ipilimumab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 (TTY: 711)
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION *(continued)* – Required clinical information must be completed in its entirety for all precertification requests.

☐ **Kaposi sarcoma**
Please indicate the type: ☐ Classic Kaposi sarcoma ☐ Other
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please indicate the place in therapy in which the requested drug will be used: ☐ First-line therapy ☐ Subsequent treatment
Please select the clinical setting in which the requested drug will be used: ☐ Relapsed/refractory disease ☐ Other

☐ **Merkel cell carcinoma**
Please indicate how the requested drug will be used: ☐ Single agent ☐ In combination with nivolumab (Opdivo) ☐ Other
Please select the clinical setting in which the requested drug will be used: ☐ Unresectable disease ☐ Recurrent disease ☐ Stage IV disease ☐ Other

☐ **Non-Small Cell Lung Cancer**
Please indicate how the requested drug will be used: ☐ In a regimen containing nivolumab (Opdivo) ☐ Other
Please indicate the clinical setting in which the requested drug will be used:
☐ Recurrent disease ☐ Metastatic disease ☐ Advanced disease ☐ Other
☐ Yes ☐ No ☐ Unknown Is the patient positive for any of the following: EGFR exon 19 deletions, L858R mutations or ALK rearrangements?
→ ☐ Yes ☐ No Is testing for these genomic tumor aberrations not feasible due to insufficient tissue?

☐ **Pleural or peritoneal mesothelioma (including pericardial mesothelioma and tunica vaginalis testis mesothelioma)**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?

☐ **Renal cell carcinoma**
Please select the clinical setting in which the requested drug will be used: ☐ Relapsed disease ☐ Advanced disease ☐ Stage IV disease ☐ Other
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please indicate how many doses of the requested drug will be given: _____
What is the histology? ☐ Clear cell ☐ Non-clear cell

☐ **Small bowel adenocarcinoma**
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?
Please indicate the clinical setting in which the requested drug will be used: ☐ Advanced disease ☐ Metastatic disease ☐ Other
☐ Yes ☐ No ☐ Unknown Is the tumor microsatellite-instability high (MSI-H) or mismatch repair deficient (dMMR)?

☐ **Soft Tissue Sarcoma**
Please indicate sarcoma type: ☐ Extremity/body wall sarcomas ☐ Head/neck sarcomas ☐ Retroperitoneal/intra-abdominal sarcomas
☐ Rhabdomyosarcoma ☐ Angiosarcoma ☐ Other
☐ Yes ☐ No Will the requested drug be used in combination with nivolumab (Opdivo)?

☐ **Uveal Melanoma**
Please indicate the clinical setting in which the requested drug will be used: ☐ Metastatic disease ☐ Unresectable disease ☐ Other
Please indicate how the requested drug will be used: ☐ Single agent ☐ In combination with nivolumab (Opdivo) ☐ Other

For All Continuation Requests (clinical documentation required):
☐ Yes ☐ No Is there evidence of disease progression or unacceptable toxicity on the current regimen?
☐ Yes ☐ No Is this infusion request in an outpatient hospital setting?
→ ☐ Yes ☐ No Is the patient continuing on a maintenance regimen that includes provider administered combination chemotherapy?
→ Please indicate the regimen:
☐ Opdivo used in combination with Yervoy for non-small cell lung cancer (NSCLC)
☐ Opdivo used in combination with Yervoy for pleural or peritoneal mesothelioma, including pericardial mesothelioma and tunica vaginalis testis mesothelioma
☐ Other, Please explain: _____
☐ Yes ☐ No Is the patient experiencing severe toxicity requiring continuous monitoring (e.g., Grade 2-4 bullous dermatitis, transaminitis, pneumonitis, Stevens-Johnson syndrome, acute pancreatitis, primary adrenal insufficiency aseptic meningitis, encephalitis, transverse myelitis, myocarditis, pericarditis, arrhythmias, impaired ventricular function, conduction abnormalities)?
→ Please explain: _____
☐ Yes ☐ No Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (e.g., acetaminophen, steroids, diphenhydramine, fluids, other pre-medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion?
→ Please explain: _____
☐ Yes ☐ No Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting?
→ Please explain: _____ _____

Continued on next page

Yervoy® (ipilimumab) Injectable Medication Precertification Request

(All fields must be completed and legible for precertification review.)

Aetna Precertification Notification
Phone: 1-866-752-7021 **(TTY:** 711**)**
FAX: 1-888-267-3277

For Medicare Advantage Part B:
Please Use Medicare Request Form

Patient First Name	Patient Last Name	Patient Phone	Patient DOB

G. CLINICAL INFORMATION ***(continued)*** – Required clinical information must be completed in its entirety for all precertification requests.

☐ Yes ☐ No Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver?
→ Please explain: _____

☐ Yes ☐ No Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the patient's ability to tolerate a large volume or load or predispose the patient to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment?
→ Please provide a description of the condition:

- ☐ Cardiopulmonary: _____
- ☐ Respiratory: _____
- ☐ Renal: _____
- ☐ Other: _____

☐ Yes ☐ No Is the patient within the initial 6 months of starting therapy?
→ Please indicate how many continuous months of treatment the patient has received with the requested drug: _____

☐ **Adjuvant treatment of melanoma only:**
Please indicate how many months of adjuvant treatment the patient has received with the requested drug: _____

☐ **Cutaneous melanoma** ☐ **Hepatocellular carcinoma** ☐ **Renal cell carcinoma**

☐ **Colorectal cancer (including appendiceal adenocarcinoma and anal adenocarcinoma) only:**
Please indicate how many doses of the requested drug the patient has already received: _____

☐ **Non-small cell lung cancer** ☐ **Esophageal cancer** ☐ **Pleural mesothelioma, including pericardial mesothelioma and tunica vaginalis testis mesothelioma only:**
Please indicate how many continuous months of treatment the patient has received with the requested drug: _____

H. ACKNOWLEDGEMENT

Request Completed By ***(Signature Required):*** _____ **Date:** ____/____/____

Any person who knowingly files a request for authorization of coverage of a medical procedure or service with the intent to injure, defraud or deceive any insurance company by providing materially false information or conceals material information for the purpose of misleading, commits a fraudulent insurance act, which is a crime and subjects such person to criminal and civil penalties.

The plan may request additional information or clarification, if needed, to evaluate requests.